BENITEC BIOPHAR/S (NASDAQ:BNTC)’s share price reached a new 52-week low during trading on Monday . The company traded as low as $1.78 and last traded at $1.78, with a volume of 6775 shares traded. The stock had previously closed at $1.92.

An institutional investor recently bought a new position in BENITEC BIOPHAR/S stock. Sphera Funds Management LTD. acquired a new position in BENITEC BIOPHAR/S (NASDAQ:BNTC) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 120,000 shares of the biotechnology company’s stock, valued at approximately $294,000. Sphera Funds Management LTD. owned approximately 1.09% of BENITEC BIOPHAR/S as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 4.67% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “BENITEC BIOPHAR/S (BNTC) Reaches New 1-Year Low at $1.78” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright legislation. The legal version of this piece can be accessed at https://www.watchlistnews.com/benitec-biophar-s-bntc-reaches-new-1-year-low-at-1-78/2676090.html.

BENITEC BIOPHAR/S Company Profile (NASDAQ:BNTC)

Benitec Biopharma Limited, a biotechnology company, develops treatments for chronic and life-threatening human diseases based on its gene silencing therapy, DNA-directed RNA interference (ddRNAi) in Australia and the United States. The company provides BB-301, a single administration ddRNAi-based gene therapy for the treatment of oculopharyngeal muscular dystrophy; BB-201, a ddRNAi-based therapy for the treatment of wet age-related macular degeneration; and BB-101 and BB-103 ddRNAi-based therapies for the treatment of human hepatitis B.

Further Reading: What is the Federal Reserve?

Receive News & Ratings for BENITEC BIOPHAR/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BENITEC BIOPHAR/S and related companies with MarketBeat.com's FREE daily email newsletter.